Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc. (NASDAQ:LXEO), filed a Form 4 on August 19, 2026, disclosing a sale of common stock on August 18, 2026, to cover tax obligations arising from the vesting of restricted stock units.

Key Highlights

  • Reporting person: Jose Manuel Otero, Chief Operating Officer of Lexeo Therapeutics, Inc.
  • Transaction: 1,304 shares of common stock disposed of (transaction code S) on August 18, 2026.
  • Purpose: According to the filing, the sale "represents a sale to cover tax obligations on the release of restricted stock units."
  • Weighted average price: $4.9571 per share, with individual trades executed at prices ranging from $4.94 to $5.01.
  • Beneficial ownership following transaction: 136,178 shares of common stock held directly, which the filing notes includes 97,026 restricted stock units.
  • Filing form: Signed by Youjin Choi as Attorney-in-Fact on August 19, 2026.

Lexeo Therapeutics COO Otero's RSU Tax-Related Share Disposition

According to the Form 4 filed with the SEC, Jose Manuel Otero, serving as Chief Operating Officer of Lexeo Therapeutics, Inc., disposed of 1,304 shares of common stock on August 18, 2026. The filing states this transaction was a sale to cover tax obligations triggered by the release of restricted stock units, a common mechanism used when RSUs vest and generate a taxable event.

The filing discloses that the transaction was executed across multiple trades at prices ranging from $4.94 to $5.01 per share. The price reported in the filing, $4.9571, reflects the weighted average sale price across those trades. The filing further notes that Otero "undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price."

Following the reported transaction, Otero's direct beneficial ownership stands at 136,178 shares of Lexeo Therapeutics common stock. The filing specifies that this total includes 97,026 restricted stock units. The Form 4 was filed by Youjin Choi as Attorney-in-Fact and is listed as a filing by one reporting person.

What Was Disclosed

The filing discloses a single disposition of 1,304 shares of Lexeo Therapeutics common stock by COO Jose Manuel Otero on August 18, 2026, at a weighted average price of $4.9571, executed to satisfy tax obligations on RSU vesting, leaving him with 136,178 shares beneficially owned directly.